Novo Nordisk A/S header image

Novo Nordisk A/S

NVO

Equity

ISIN null / Valor 461641

New York Stock Exchange, Inc (2026-08-04)
USD 44.28-5.97%

Novo Nordisk A/S
UMushroom community rating:

star star star star star
4.10 23 votes No rating yet
NegativeNeutralPositive

About company

Novo Nordisk A/S is a Danish multinational pharmaceutical company focused principally on diabetes care and related metabolic disorders, developing, manufacturing and commercializing medicines and delivery devices—most prominently insulin and GLP‑1 receptor agonists used in type 2 diabetes and obesity treatment—and it also markets therapies for haemophilia, growth disorders and hormone replacement. The company combines clinical research and development with large‑scale manufacturing and worldwide commercial operations and is publicly listed on the Copenhagen stock exchange. Internally, Novo Nordisk operates under corporate conduct frameworks (OneCode and the Novo Nordisk Way) that define expected standards of behaviour and decision‑making for employees.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-9.28%1Y
-43.4%3Y
-9.85%5Y

Performance

47.1%1Y
44.7%3Y
39.2%5Y

Volatility

Market cap

148939 M

Market cap (USD)

Daily traded volume (Shares)

47,478,812

Daily traded volume (Shares)

1 day high/low

86.86 / 85.69

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.10

23 votes
Performance:
starstarstarstarstar
3.82
Innovation:
starstarstarstarstar
4.38
Society:
starstarstarstarstar
4.09
Nature:
starstarstarstarstar
4.02
Paulina María Herrera Ovalle
Spain, 30 Apr 2026
star star star star star
It has potential
Fabio Kull
Switzerland, 21 Mar 2026
star star star star star
Novo Nordisk is attractive due to its leadership in diabetes and obesity treatments.
Paulina María Herrera Ovalle
Spain, 20 Mar 2026
star star star star star
Promising long term

EQUITIES OF THE SAME SECTOR

Essity AB
Essity AB Essity AB Valor: 36851944
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.43%SEK 277.20
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB Valor: 2676862
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.05%SEK 436.20
Smith & Nephew PLC
Smith & Nephew PLC Smith & Nephew PLC Valor: 1111046
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.32%USD 30.44
Centene Corp
Centene Corp Centene Corp Valor: 1313733
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.49%USD 64.07
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc Ionis Pharmaceuticals Inc Valor: 30877188
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.06%USD 55.07
Option Care Health Inc
Option Care Health Inc Option Care Health Inc Valor: 52359365
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.04%USD 23.69
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc Madrigal Pharmaceuticals Inc Valor: 33395434
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.30%USD 507.56
HealthEquity Inc
HealthEquity Inc HealthEquity Inc Valor: 24679014
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.58%USD 104.97
Ensign Group Inc
Ensign Group Inc Ensign Group Inc Valor: 3109721
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.62%USD 176.13
Bright Horizons Family Solutions
Bright Horizons Family Solutions Bright Horizons Family Solutions Valor: 19920287
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.88%USD 75.60